KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Treasury Shares (2016 - 2026)

Bio-Rad Laboratories has reported Treasury Shares over the past 15 years, most recently at $1.1 billion for Q1 2026.

  • Quarterly Treasury Shares rose 21.47% to $1.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Mar 2026, up 21.47% year-over-year, with the annual reading at $1.0 billion for FY2025, 30.76% up from the prior year.
  • Treasury Shares was $3.4 million for Q1 2026 at Bio-Rad Laboratories, up from $3.3 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $4.1 million in Q2 2025 and troughed at $279544.0 in Q1 2022.
  • The 5-year median for Treasury Shares is $2.3 million (2024), against an average of $2.0 million.
  • The largest YoY upside for Treasury Shares was 147.99% in 2022 against a maximum downside of 29.1% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $263.6 million in 2022, then surged by 139.96% to $632.5 million in 2023, then increased by 22.07% to $772.1 million in 2024, then soared by 30.76% to $1.0 billion in 2025, then grew by 4.3% to $1.1 billion in 2026.
  • Per Business Quant, the three most recent readings for BIO's Treasury Shares are $1.1 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025).